Literature DB >> 36202492

Effectiveness of COVID-19 Booster on the Risk of Hospitalization Among Medicare Beneficiaries.

Hemalkumar B Mehta1, Shuang Li2, James S Goodwin2.   

Abstract

OBJECTIVE: To determine the effectiveness of booster vaccinations on the risk of hospitalization with coronavirus disease 2019 (COVID-19) and how it varies by enrollee characteristics and interval from the initial vaccination to receipt of a booster. PATIENTS AND METHODS: This cohort study used 100% Medicare claims from January 1, 2020, through December 31, 2021, and matched 3,940,475 individuals who received boosters to 3,940,475 controls based on week and type of original COVID-19 vaccine and demographic and clinical characteristics. We compared the association of booster vs no booster with COVID-19 hospitalization using Cox proportional hazards regression models controlling for patient characteristics. We also determined the association of time from original vaccine to booster with COVID-19 hospitalization.
RESULTS: Over a maximum of 130 days of follow-up, boosted enrollees had 8.20 (95% CI, 7.81 to 8.60) COVID-19 hospitalizations per million days vs 43.70 (95% CI, 42.79 to 44.64) for controls (81% effectiveness). Effectiveness varied by race, prior hospitalizations, and certain comorbidities, for example, leukemia/lymphoma (53% effectiveness), autoimmune disease (73%), and dementia (73%). Boosters received between 6 and 9 months after original vaccination varied between 81% and 85% effectiveness, while boosters received at 5 to 6 months (62%) or less than 5 months (58%) were less effective.
CONCLUSION: Boosters are highly effective in the Medicare population. Approximately 69,225 hospitalizations would be prevented by boosters in the 15 million individuals aged 65 years or older currently not boosted in a period similar to the September 2020 through January 2021 period studied. Boosters provided the greatest benefits if they were received between 6 and 9 months following original vaccinations. However, boosters were associated with substantial decreases in COVID-19 hospitalizations in all categories of enrollees.
Copyright © 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36202492      PMCID: PMC9273609          DOI: 10.1016/j.mayocp.2022.06.029

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   11.104


  18 in total

1.  Uptake and Accuracy of the Diagnosis Code for COVID-19 Among US Hospitalizations.

Authors:  Sameer S Kadri; Jake Gundrum; Sarah Warner; Zhun Cao; Ahmed Babiker; Michael Klompas; Ning Rosenthal
Journal:  JAMA       Date:  2020-12-22       Impact factor: 56.272

2.  Covid-19 vaccine trials: Ethnic diversity and immunogenicity.

Authors:  Hannah Jethwa; Richard Wong; Sonya Abraham
Journal:  Vaccine       Date:  2021-05-11       Impact factor: 3.641

3.  Comparison of methods to identify long term care nursing home residence with administrative data.

Authors:  James S Goodwin; Shuang Li; Jie Zhou; James E Graham; Amol Karmarkar; Kenneth Ottenbacher
Journal:  BMC Health Serv Res       Date:  2017-05-30       Impact factor: 2.655

4.  Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets.

Authors:  Ge Liu; Brandon Carter; David K Gifford
Journal:  Cell Syst       Date:  2020-11-27       Impact factor: 10.304

5.  Substantial underestimation of SARS-CoV-2 infection in the United States.

Authors:  Sean L Wu; Andrew N Mertens; Yoshika S Crider; Anna Nguyen; Nolan N Pokpongkiat; Stephanie Djajadi; Anmol Seth; Michelle S Hsiang; John M Colford; Art Reingold; Benjamin F Arnold; Alan Hubbard; Jade Benjamin-Chung
Journal:  Nat Commun       Date:  2020-09-09       Impact factor: 14.919

6.  Risk Factors Associated With SARS-CoV-2 Infections, Hospitalization, and Mortality Among US Nursing Home Residents.

Authors:  Hemalkumar B Mehta; Shuang Li; James S Goodwin
Journal:  JAMA Netw Open       Date:  2021-03-01

7.  Extended interval BNT162b2 vaccination enhances peak antibody generation.

Authors:  Helen Parry; Rachel Bruton; Christine Stephens; Christopher Bentley; Kevin Brown; Gayatri Amirthalingam; Bassam Hallis; Ashley Otter; Jianmin Zuo; Paul Moss
Journal:  NPJ Vaccines       Date:  2022-01-27       Impact factor: 9.399

8.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.

Authors:  Hiam Chemaitelly; Patrick Tang; Mohammad R Hasan; Sawsan AlMukdad; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar H Kaleeckal; Ali N Latif; Riyazuddin M Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed G Al Kuwari; Hamad E Al Romaihi; Adeel A Butt; Mohamed H Al-Thani; Abdullatif Al Khal; Roberto Bertollini; Laith J Abu-Raddad
Journal:  N Engl J Med       Date:  2021-10-06       Impact factor: 91.245

9.  Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.

Authors:  Mark G Thompson; Karthik Natarajan; Stephanie A Irving; Elizabeth A Rowley; Eric P Griggs; Manjusha Gaglani; Nicola P Klein; Shaun J Grannis; Malini B DeSilva; Edward Stenehjem; Sarah E Reese; Monica Dickerson; Allison L Naleway; Jungmi Han; Deepika Konatham; Charlene McEvoy; Suchitra Rao; Brian E Dixon; Kristin Dascomb; Ned Lewis; Matthew E Levy; Palak Patel; I-Chia Liao; Anupam B Kharbanda; Michelle A Barron; William F Fadel; Nancy Grisel; Kristin Goddard; Duck-Hye Yang; Mehiret H Wondimu; Kempapura Murthy; Nimish R Valvi; Julie Arndorfer; Bruce Fireman; Margaret M Dunne; Peter Embi; Eduardo Azziz-Baumgartner; Ousseny Zerbo; Catherine H Bozio; Sue Reynolds; Jill Ferdinands; Jeremiah Williams; Ruth Link-Gelles; Stephanie J Schrag; Jennifer R Verani; Sarah Ball; Toan C Ong
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-01-21       Impact factor: 35.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.